Glibenclamide and thymoquinone plasma concentrations were analysed using a sensitive RP-HPLC method, and non-compartmental model pharmacokinetic parameters were calculated. The maximum reduction in blood glucose level was observed 3 hours following glibenclamide administration, which reached 47.4% of baseline, whereas it was reduced by 53.0% to 56.2% when co-administrated with thymoquinone. Plasma concentration of glibenclamide was increased by 13.4% and 21.8% by the co-administration of thymoquinone as single and multiple doses, respectively (P<0.05). The AUC and T1/2 of glibenclamide were also increased respectively by 32.0% and 17.4% with a thymoquinone single dose, and by 52.5% and 92.8% after chronic treatment. Furthermore, diabetic rats treated with thymoquinone demonstrated a marked decrease in hepatic protein expressions of CYP3A2 and CYP2C11 enzymes that are responsible for the metabolism of glibenclamide. The current data suggest that thymoquinone exhibits a synergistic effect with glibenclamide on glucose level, which could be explained by reducing CYP450 activity at the protein level.
Diabetes mellitus is a growing health problem in both developed and developing countries [1] . This disorder in managed symptomatically by a variety of drugs that act through increasing insulin secretion and/or reducing insulin resistance [2, 3] . Sulfonylureas are commonly used drugs in the treatment of type II diabetes [4, 5] . Glibenclamide, a second generation sulfonylurea, has selective inhibitory activity towards ATP-sensitive K + (KATP) channels on the cell membrane of pancreatic beta cells, which open voltage-gated Ca 2+ channels. The rise in intracellular calcium leads to increased synthesis of insulin within the cell membrane, and therefore, increased secretion of pro-insulin [6] . Despite the availability of various classes of anti-diabetic drugs, the quest for new therapies is far from ending. In particular, compounds from natural resources have been used in many parts of the world as an alternative or complementary medicine to treat diabetes [7] .
Due to its properties, the traditional herb Nigella sativa (or black seed) of the family Ranunculaceae has been used as an anti-diabetic and hepatoprotective agent, especially when liver dysfunction exists [8] . It is therefore possible that N. sativa seeds are concomitantly consumed with the oral hypoglycemic agents such as sulfonylureas. [9, 10] . Thymoquinone is the main active constituent of N. sativa. The black seeds contain essential and fixed oils, proteins, alkaloids and saponin. The biological activity of N. sativa has been shown to be due to its principle chemical constituent thymoquinone [11] . It has been shown that thymoquinone can inhibit liver drugmetabolizing phase I cytochrome P450 (CYP) enzymes [12] , but it is unknown whether it affects the metabolism and the hypoglycemic effect of sulfonylureas. Therefore, the aim of the present study is to investigate the effect of thymoquinone on the pharmacokinetics and pharmacodynamics of glibenclamide in a diabetic model induced with streptozotocin [13, 14] .
Diabetes was successfully induced in rats by the administration of streptozotocin and confirmed by the elevation of blood glucose levels to ~590 mg/dL. Streptozotocin is often used to induce diabetes in experimental animals through its toxic effects on pancreatic β-cells and as a potential oxidative stress inducer [15] . As expected, treatment with glibenclamide reduced blood glucose levels in a time dependent manner (p < 0.01). The maximum reduction of blood glucose level was observed 3 hours after glibenclamide treatment and reached 47.4% of baseline, while it was 53.0% with the concomitant administration of a single dose of thymoquinone. In the multiple dose interaction study, thymoquinone showed a slightly more synergetic effect with glibenclamide causing 56.2% reduction in glucose level, as shown in Figure 1 .
The estimated pharmacokinetic parameters of glibenclamide, alone and when co-administered with thymoquinone, are listed in Table 1 and plasma drug concentration profiles are illustrated in Figure 2 . The co-administration of thymoquinone as single or multiple doses led to increases in Cmax, Tmax and AUC0-t of glibenclamide, as As shown in Figure 3 , hepatic CYP3A2 and CYP2C11 protein expressions were markedly decreased following thymoquinone treatment as compared with β-actin controls. This reached 58% and 61% down-regulation in CYP3A2, and 67% and 70% reduction in CYP2C11 protein following single and multiple doses of thymoquinone, respectively (p< 0.05). Furthermore, thymoquinone, given alone or concurrently with glibenclamide, ameliorated increased plasma levels of ALT and AST caused by streptozotocin administration in rats ( Table 2) .
Drug interactions are commonly seen in clinical practice and initial mechanisms of interactions are usually evaluated in animal models [16] . It has been shown that the hypoglycemic effect of glibenclamide can be modulated with the co-administration of CYP inhibitors such as ciprofloxacin [17] . Hence, it is necessary to evaluate the effect of commonly used drugs and herbal products on the pharmacokinetics and dynamics of oral hypoglycemic agents in order to avoid potential adverse reactions, especially hypoglycemia. Nigella sativa is widely used for its various proposed therapeutic effects and culinary purposes. The current findings showed that the pharmacokinetics and the hypoglycemic effect of glibenclamide can be altered when it is co-administrated with thymoquinone as single and multiple doses.
These aforesaid findings show that thymoquinone can inhibit the metabolism of glibenclamide by inhibiting CYP3A4, CYP2C9 and CYP2C19 enzymes in the liver [18, 19] . This translated into a reduction in glibenclamide systemic clearance and a prolongation of its T1/2, as observed in the current study. In fact, there are several reports showing that thymoquinone can inhibit various CYP isoenzymes including CYP3A4 and CYP2C9 [20] [21] [22] [23] . The catalytic properties of rat CYP3A2 and CYP2C11 are similar to those of human CYP3A4 and CYP2C9 [24] . Despite the role of CYP2C19 in the metabolism of glibenclamide, only inhibition of CYP3A4 and CYP2C9 activities leading to changes in pharmacokinetics and the glucose-lowering effect of glibenclamide can be postulated. Finally, the increase in ALT and AST levels indicated that streptozotocininduced diabetes can be associated with hepatic injury [25] [26] [27] [28] . Glibenclamide showed no effect on those changes, but thymoquinone protected against liver damage as measured by normalization of liver transaminases levels.
The effects of thymoquinone on the pharmacodynamics and pharmacokinetics of glibenclamide suggest that it can affect the metabolism of glibenclamide in diabetic rats, possibly by the inhibition of CYP3A2 and CYP2C11. Also, the concomitant use of thymoquinone increases the glucose-lowering effect of glibenclamide. According to the guidance of the rational administration principle, whether the combination of glibenclamide and thymoquinone can be used in humans is worthy of further studying. House Facility of King Saud University (Riyadh, Saudi Arabia) and maintained in standard plastic animal cages in groups of 6 animals each with a 12 h light and dark cycle at 23±1ºC in accordance with the recommendations approved by the facility and the college's Ethics Committee. The rats were fed on standard rat chow and provided water ad libitum and acclimatized to laboratory conditions for a week prior to experiments.
Experimental

Drugs and chemicals:
Diabetes model:
Diabetes was induced after an overnight fast by the administration of streptozotocin prepared in citric acid buffer (pH 4.5) at a dose of 60 mg/kg intraperitoneally [29] . After 1 h of administration, the rats were allowed chow and water ad libitum and kept under observation for the determination of fasting blood glucose levels measured 72 h from diabetes induction. Animals that developed blood glucose levels >250 mg/dL (checked by glucose strips) were considered diabetic and included in the study.
Study protocol:
The diabetic rats were distributed into 5 groups each of 6 animals. Before the experiment, all animals were fasted for 12 h except for a free access to water. After collection of initial blood samples, drugs were administered in the following order: Group I was treated with normal saline and served as a diabetic control; Group II was treated with glibenclamide (10 mg/kg p.o.); Group III was given thymoquinone alone (10 mg/kg p.o.); Group IV was pretreated with thymoquinone (10 mg/kg p.o.) as a single dose followed by glibenclamide (10 mg/kg p.o.) after 60 min; and Group V was pretreated with thymoquinone (10 mg/kg p.o.) for 7 days. On the 8th day, thymoquinone administration was followed by glibenclamide (10 mg/kg p.o.) after 60 min.
Biochemical analysis:
Blood samples were withdrawn into heparinized tubes from the retro-orbital venous plexus under light ether anesthesia and plasma was separated by centrifugation. Blood glucose levels were checked by glucose strips. Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed using commercial kits (Human Diagnostic Worldwide, Wiesbaden, Germany). At the end of the experiment, rats were sacrificed under anesthesia and the livers were excised. Liver microsomes were prepared by differential ultra-centrifugation and protein was assayed by the method of Lowry [30] .
Pharmacokinetic evaluation:
Following an overnight fast, glibenclamide was administered orally to male albino Waster rats at an oral dose of 10 mg/kg (prepared in 10% DMSO). Blood samples were collected from the retro-orbital plexus in tubes containing disodium EDTA at 0, 15, 30, 60, 90, 120, 180, 240, 360, 720 and 1440 min post-dosing. Plasma was separated by centrifugation at 2500×g for 10 min and transferred into pre-labeled Eppendrof tubes for subsequent analysis.
Glibenclamide plasma concentrations were measured using a validated high performance liquid chromatographic (HPLC) analytical method with a lower limit of quantification set at 0.332 μg mL −1 for glibenclamide [31] . Western blot: Western blot analysis for the expression of CYP3A2 and CYP2C11 proteins was performed according to Towbin et al. [32] . The liver proteins were electrophoretically transferred to PVDF membranes, and blocked in 5% skim milk in Tris buffer saline (TBS) containing 1% Tween 20 for 2 h at room temperature. The membranes were probed with polyclonal CYP3A2 (sc-25845), CYP2C11 (LS-C64214) and β-actin (sc-47778) rabbit-anti rat antibodies as solutions in PBS containing 1% Tween 20 on a shaker for 2 h at room temperature, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (1:3000) for 1 h and visualization with the enhanced chemiluminescence system of Santa Cruz Biotechnology (Dallas, Texas, USA). Total proteins densitometric analysis of the immunoblots was performed using Image J analysis software (National Institutes of Health) and β-actin as a loading control.
Statistical analysis:
The data are expressed as mean with standard error of mean (SEM). The significance was determined by applying one-way ANOVA using Graph Pad Prism version 6 for Windows (Graph Pad Software, San Diego, CA, USA). P values <0.05 were considered significant.
